MB BCh BAO, FCICM, MD, FFA RCSI, MSc (Anaes), DIBICM, PG Dip Echo
Martina graduated from the National University of Ireland, Galway in 1997. She was admitted by Fellowship to the College of Anaesthetists of Ireland in 2001 and completed her specialist training in Anaesthesia in Ireland in 2007. During this time she completed a Masters of Medical Science in Anaesthesia. She was awarded a Doctor of Medicine Degree in 2009 for her thesis based on research carried out at NUI Galway from 2004-2006. She moved to Australia in 2008 and was admitted as a Fellow to the College of Intensive Care Medicine in 2009. She has been working as a staff specialist in Intensive Care at Geelong since 2010.
Her areas of interest include Safety and Quality of care delivery, Rapid Response Systems and the Deteriorating Patient, ECMO and Echocardiography. She is a member of the Deteriorating Patient Committee, Antimicrobial Stewardship Committee and Central Venous Catheter Working Group.
Head of ECMO
Martina is the Head of the UHG ICU ECMO service, the 2nd largest adult ECMO program in Victoria.
Latest news:
-
Thursday, April 8, 2021 - 16:13
JAMA BACLOREA High-dose baclofen reduced agitation-related events in adult patients with unhealthy alcohol use requiring mechanical ventilation. However secondary outcomes of deeper sedation, longer duration of mechanical ventilation, prolonged ICU care = more research
Tuesday, April 6, 2021 - 14:25JAMA Mechanical ventilation weaning practices vary internationally, regard to the use of protocols, screening for and conducting SBTs, adjustment of ventilator support, and the responsibility of clinicians involved in weaning
Tuesday, April 6, 2021 - 12:01JAMA HENIVOT Trial -Helmet NIV vs HFNC for critically ill patients with mod-severe hypoxemic COVID resp failure = no diff in the resp support fee days (28 d). Secondary diff in intubation, lower in helmet group, ie overall no difference in 28-d resp support, but helmet lower proportion of this time intubated.
Friday, February 19, 2021 - 07:30JAMA RCT does not support use of single high dose oral vitamin D3 for treatment of moderate to severe COVID-19 in hospitalized patients. Limitations in design, however, confirms lack of benefit reported in multiple large non-COVID trials in hospital or ICU patients (VIOLET, VITdAL-ICU)
Sunday, February 14, 2021 - 09:30NEJM DePPaRT: 1% of patients with loss of cardiac activity after planned withdrawal of life sustaining therapy have transient resumption of cardiac activity observable by bedside reports and corroborated by ECG and IABP waveform activity. Retrospective waveform review showed resumption of cardiac activity in 14% of patients. The longest period of pulselessness that was followed by resumption of cardiac activity was 4 minutes 20 seconds.